Release date: December 1, 2006
Review date: October 24, 2007
Available for credit through: December 31, 2008
Program Description
Anemia is common in cancer patients, but the impact is often poorly appreciated. It is a major cause of tumor hypoxia, a condition that can further tumor survival and malignant progression and also reduces the effectiveness of several anticancer therapies, including radiotherapy and oxygen-dependent cytotoxic agents.
Clinical studies in patients with solid tumors and non-myeloid hematologic malignancies have convicingly shown that treatment with erythropoetic stimulating factors (ESPs) improves mean hemoglobin concentration, reduces transfusion requirement, and improves quality of life. Despite the availability of effective treatment, patients of cancer- or chemotherapy-associated anemia remain under-treated. Strategies for incorporating clinical guidelines into practice and the safety and pharmacoeconomic issues surrounding treatment of anemia with ESPs will be discussed in this activity.
Target Audience
This program is designed specifically for Hematologists, Medical Oncologists, Pharmacists, Oncology Nurses, Physician Assistants, and Certified Case Managers caring for patients receiving chemotherapy for cancer.
Educational Objectives
Upon completion of this activity, participants will be able to:
Describe the central role of the management of anemia in prognosis and quality of life in cancer patients (with or without chemotherapy)
Identify and assess the latest treatment options in erythropoietin stimulating proteins (ESPs) for the management of cancer / chemotherapy-induced anemia
Evaluate and apply the evolving guidelines of early ESP treatment (at Hb<11 gm/dL) for cancer / chemotherapy-induced anemia
There are no fees to participate in this activity. A certificate of completion for physicians and nurses and a statement of credit for pharmacists may be printed out after viewing the program and submitting your post-test and evaluation form.
Accreditation
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ArcMesa Educators designates this educational activity for a maximum of 1.5 AMA PRA Category 1 creditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. (UPN 200-000-06-028-H01-P). Pharmacists will receive 1.5 contact hours (0.15 CEUs) for successful completion of this activity.
ArcMesa Educators is an approved provider of continuing education in nursing by the ASNA, an accredited approver by the ANCC Commission on Accreditation. Participants are entitled to receive 1.5 contact hour upon successful completion of the activity.
Faculty Disclosure Declarations
Leon E. Cosler, RPh, PhD – Unrestricted Research Support and Honorarium – Amgen
John Glaspy, MD, MPH – Research Support Recepient – Amgen, Ortho Biotech
Gary H. Lyman, MD, MPH, FRCP (Edin) – Research Support Recepient and Speakers’ Bureau – Amgen
Christopher R. Friese, RN, PhD, AOCN® – Consultant, Speakers’ Bureau/Honorarium recipient, Stock Shareholder – Amgen; Stock Shareholder – Novartis
Don Tessier (Medical Writer) – Nothing to disclose
Shanna J. McClennen, PhD (Medical Writer) – Nothing to disclose
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Amgen, any other manufacturer of pharmaceuticals, or ArcMesa Educators.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
Gary H. Lyman, MD, MPH, FRCP (Edin)
Professor of Medicine and Oncology
University of Rochester School of Medicine and Dentistry
Director, Health Services and Outcomes Research
James P. Wilmot Cancer Center University of Rochester Medical Center Strong Memorial Hospital
Christopher R. Friese, RN, PhD, AOCN®
Research Fellow
Center for Outcomes & Policy Research
Dana-Farber Cancer Institute/Harvard School of Public Health
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. (UPN 200-000-06-028-H01-P). Pharmacists will receive 1.5 contact hours (0.15 CEUs) for successful completion of this activity.
